Autonomix Medical, Inc. Announces Leadership Changes
Autonomix Medical, Inc., a renowned medical device company dedicated to transforming the diagnosis and treatment of nervous system diseases, has recently made significant changes to its executive team. Brad Hauser has been appointed as the new President and Chief Executive Officer, succeeding Lori Bisson, who has transitioned to the role of Executive Vice Chairman. These changes aim to propel the company into its next phase of growth and development.
Brad Hauser: A Visionary Leader in Medical Technology
Brad Hauser, the newly appointed President and CEO of Autonomix, brings with him over 20 years of experience in the medical technology industry. With a proven track record of successfully navigating the complexities of bringing innovative technologies to market, Hauser is well-equipped to lead Autonomix into a new era of growth and success. His background includes leadership roles at prominent companies such as Soliton, Inc., ZELTIQ Aesthetics, and Reliant Technologies, where he played pivotal roles in driving acquisitions and fostering innovation.
Lori Bisson’s Strategic Transition to Executive Vice Chairman
Formerly serving as President and CEO, Lori Bisson has assumed the role of Executive Vice Chairman at Autonomix. Her strategic leadership and transformative efforts have laid a solid foundation for the company’s future success. Bisson’s transition to this new role signifies a continued commitment to guiding Autonomix through its corporate and capital market strategies.
Exciting Opportunities Ahead
In a statement regarding the leadership changes, Walter Klemp, Executive Chairman of Autonomix, expressed gratitude for Lori Bisson’s foundational work and welcomed Brad Hauser’s expertise to drive the company forward. Both Bisson and Hauser have shared their enthusiasm for collaborating once again, highlighting the potential for Autonomix to revolutionize the diagnosis and treatment of nervous system diseases. With a focus on advancing novel technologies and enhancing patient outcomes, Autonomix is poised to make a significant impact in the healthcare industry.
Industry Recognition and Achievements
Hauser’s extensive experience in the medical technology field, coupled with Bisson’s strategic vision, positions Autonomix for continued success. Hauser’s background includes key roles at Beauty Health, Soliton, and ZELTIQ Aesthetics, where he spearheaded transformative initiatives and drove innovation. His expertise in tissue coagulation and ablation systems, combined with a history of successful product launches, makes him a valuable addition to Autonomix’s leadership team.
Investment in Innovation
In recognition of Hauser’s appointment, the Compensation Committee of Autonomix’s Board of Directors approved an inducement stock option grant. This grant underscores the company’s commitment to attracting top talent and fostering a culture of innovation. Hauser’s leadership, coupled with Autonomix’s cutting-edge technology platform, positions the company as a trailblazer in the field of nervous system disease diagnosis and treatment.
Looking Towards the Future
As Autonomix embarks on its next phase of growth, the company remains dedicated to advancing innovative technologies that revolutionize healthcare. With a focus on pain management and a clinical trial targeting pancreatic cancer, Autonomix’s technology platform holds promise for addressing a wide range of indications. By leveraging Hauser’s leadership and expertise, Autonomix is well-positioned to make significant strides in transforming patient outcomes and shaping the future of healthcare.
For more information about Autonomix Medical, Inc., visit autonomix.com.
—
Contact:
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com